Search results

  1. J

    You Might Have Already Fallen for MAHA’s Conspiracy Theories

    I think what went wrong was social media where everyone has a bullhorn, not so much main stream media.
  2. J

    You Might Have Already Fallen for MAHA’s Conspiracy Theories

    “How does someone become an anti-vaxxer or come to believe that chemotherapy is more dangerous than cancer? It can begin with what seems like a harmless health tip: Cut seed oils or artificial food dyes from your diet. From there, the road can get treacherous. It’s paved with good intentions...
  3. J

    You Might Have Already Fallen for MAHA’s Conspiracy Theories

    Well done video—American emphasis https://www.nytimes.com/2025/09/09/opinion/maha-health-wellness-influencers.html?unlocked_article_code=1.kk8.H8EO.zCl56IzdgyAe&smid=url-share
  4. J

    Proximity to Golf Courses and Risk of Parkinson Disease, 2025, Krzyzanowski et al

    The clue to unlocking Parkinson’s may be all around us. https://www.nytimes.com/2025/09/08/opinion/parkinsons-pesticides-chemicals.html?unlocked_article_code=1.kU8.TQT-.07HUDA8qHiBH&smid=nytcore-ios-share&referringSource=articleShare
  5. J

    Community Symposium on the Molecular Basis of ME/CFS Sept 5 (Stanford/Ron Davis)

    (Her email is in the link below) https://med.stanford.edu/jameslab/team.html
  6. J

    Trial Report Plasma cell targeting with the anti-CD38 antibody daratumumab in ME/CFS -a clinical pilot study, 2025, Fluge et al

    Actually @Jonathan Edwards has brought up Alemtuzumab (Campath)—a T cell depleting drug before as a possible/potential treatment.
  7. J

    Community Symposium on the Molecular Basis of ME/CFS Sept 5 (Stanford/Ron Davis)

    Bumping this thread—the community symposium starts in 10 minutes.
  8. J

    Community Symposium on the Molecular Basis of ME/CFS Sept 5 (Stanford/Ron Davis)

    R I definitely don’t discount the ability of “citizen scientists” to come up with good ideas or analyses, but not necessarily these individuals.
  9. J

    Community Symposium on the Molecular Basis of ME/CFS Sept 5 (Stanford/Ron Davis)

    Yes, but this conference is not an OMF event—it is an event of the Stanford MECFS collaborative Research Center.
  10. J

    Community Symposium on the Molecular Basis of ME/CFS Sept 5 (Stanford/Ron Davis)

    Janet Dafoe Anyone have message to these researchers? I will read it to them at the end. please make it positive. Thank you.
  11. J

    Community Symposium on the Molecular Basis of ME/CFS Sept 5 (Stanford/Ron Davis)

    Fluge/Mella attended these meetings a couple of years ago, but have not attended recently. Wonder if there is any bad blood? I know this isn’t an OMF event, but Fluge is still on the Scientific Advisory Board of OMF.
  12. J

    Community Symposium on the Molecular Basis of ME/CFS Sept 5 (Stanford/Ron Davis)

    Day 3–there is an unfortunate speaker here, unfortunately.
  13. J

    News from the USA, United States of America

    Florida Says It Plans to End All Vaccine Mandates https://www.nytimes.com/2025/09/03/us/florida-says-it-plans-to-end-all-vaccine-mandates.html?unlocked_article_code=1.jE8.VWNE.o_DhzuwrIRIq&smid=url-share Relevance to ME/CFS: If you have ME/CFS and then you get measles on top of that, then that...
  14. J

    Trial Report Patient-reported improvements from use of IMC-2 alone and IMC-2 and Paxlovid® in a Long COVID cohort: a case series, 2026, Pridgen et al

    Where is the paxlovid only treatment??? Probably didn’t want to show that you don’t need the IMC-2.
  15. J

    Trial Report Patient-reported improvements from use of IMC-2 alone and IMC-2 and Paxlovid® in a Long COVID cohort: a case series, 2026, Pridgen et al

    IMC-2 is a novel combination of Valacyclovir and Celecoxib that may have utility in addressing persistent or reactivating herpesviruses and may be relevant to the clinical care of people with Long COVID. Pridgen has been pushing this stuff for a while.
  16. J

    Baseline IGG4 levels and drug response—what’s going on?

    In the Daratumumab trial patients with higher baseline IGG4 levels tended to be drug responders whereas in the cyclo trial low IGG4 patients tended to be responders. Given all the caveats about low sample sizes, etc., wonder if anyone knows what might be going on here.
  17. J

    Long-lived plasma cell (LLPC) theory - Similarities between CFS and Lupus?

    OK in my haste I got this wrong. The non-responders were in blue—my bad. So please ignore the thing I wrote below. But it is the reverse of the dara trial—in the cyclo study high IGG4 were non-responders. Wait a minute!!! If you look at the cyclo data for IGG4 we see the same phenomenon as...
Back
Top Bottom